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Summary To establish whether loss of heterozygosity (LOH) for chromosome 16q in Wilms' tumours confers an adverse prognosis, DNA
from 40 Wilms' tumour/normal pairs were analysed using highly polymorphic microsatellite markers along the length of 16q. Fifteen per cent
of tumours showed LOH for 16q. Although the common region of allele loss spanned the 16q24-qter region, a second distinct region of LOH
was identified in 16q21. Five out of six tumours showing LOH were either (1) high stage or (2) low stage with unfavourable histology. In
addition, there was a higher mortality rate in patients showing LOH for 16q than those that did not. These data strongly support the suggestion
that LOH for 16q is associated with an adverse prognosis.
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The overall cure rate for Wilms' tumour is nowv 85%7c. a conse-
quence of consistent improvement in treatment strategies
(D'Ancio et al. 1989: Pritchard et al. 1995). Refinement oftherapy
has been based on the traditional prognostic factors of tumour
histology and the clinicopathological stage. However. these factors
have their limitations. For example. histological 'anaplasia' is
found in only 5% ofWilms' tumours and is partly stagye dependent.
conferring an adverse prognosis in stage 2. 3 and 4 tumours. but
not in stage 1 disease (D'Angio et al. 1981). The addition of
doxorubicin to vincristine and actinomycin D in the National
Wilms' Tumour Study (NWTS-3) improxed the relapse-free
sun-ival bv 10%c and the overall survival by 5% in patients with
favourable histology' stage 3 disease (D'Angio et al. 1989). In
other words. among children with stagye 3 disease. there is a subset
of patients that benefit from the addition of doxorubicin. although
the majority may still be cured w-ithout using this drug. This
improvement in sunrival is. however. achieved at a price. as the
use of doxorubicin is associated with considerable cardiac late
effects (Goonrn et al. 1990: Sorenson et al. 1995). Clearly. ifwe are
to continue to improve the outcome of patients with Wilms'
tumour. Vihile minimizincr the late effects ofcurative therapy. new
prognostic factors are required.
Cytogenetic abnormalities of chromosome 16 has-e been
reported in 30%7 of Wilms' tumour and predominantly involve the
long arm (Slater et al. 1992: Austruy et al. 1995). Two regions of
interest have been identified from these studies. a proximal locus
at 16q 1-13 and a more distal region involving 16q2l-24-qter
(Slater et al. 1992). An identical translocation. der
(16)t(l:16)(q21:ql3). has also been reported in four Wilms'
tumours (Solis et al. 1988: Wan--Wuu et al. 1990). and a der
(16)t(l:16)(ql2:ql2) was reported by Kaneko et al (1991).
Tumour-specific allelic loss has been thought to represent the
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second hit. resulting in the inactiN-ation of a tumour-suppressor
gene and can be detected by LOH analysis (Knudson and Strongy.
1972: Cavenee et al. 1983). Molecular studies have found LOH for
polymorphic markers on 16q in 10-25%7 of Wilms' tumours
(Coppes et al. 1992: Maw et al. 1992: Grundy et al. 1994: Austruy
et al. 1995: Redeker et al 1996). Using a panel of informative
markers for the region 16ql2.2-qter. Maw et al (1992) were the
first to demonstrate LOH for 16q in 9 (20%c) of 45 informatiVe
patients by Southem blot analysis. A larger follow--on study. as
part ofNWTS4. involving 232 patients. found a similar frequency
of LOH at 17%7. but used only polymorphic markers that mapped
to the distal 16q22-qter region (Grundv et al. 1994). In the study
by Coppes et al (1992). using only two polymorphic markers
mapping to 16q22.2 and 16q24.3. LOH was identified in 20% of
tumours. The most recent studv. albeit in a relatively small group
of patients (Austruy et al. 1995). found the highest level of LOH
(25%7c) using a large panel ofrestriction length polymorphisms and
microsatellite probes. Furthermore. LOH for 16q has been associ-
ated with a worse outcome because these patients have a relapse
rate 3.3 times higher than those with tumours retaining heterozy-
gosity for 16q (Grundy et al 1994).
Because cytogenetic and molecular studies of Wilms' tumours
clearly suggest a role for grenes on 16q in the molecular pathology
ofthis tumour. we have undertaken LOH analysis for 16q markers
using a large. well-characterized series of sporadic Wilms'
tumours. Our results clearly show that LOH is relatively frequent
in Wilms' tumours. especially in patients with an adverse
outcome.
MATERIALS AND METHODS
DNA was prepared from tumour tissue and lymphocNies using stan-
dard phenol-chloroform extraction procedures described by Wadeyet
al (1990).The optimal polymerase chain reaction (PCR) conditions
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Table 1 Microsatelite repeat priner pairs for chromosome 16q LOH analysis
Locus Physical Heterozygosity CA strand primer GT strand primer Size range [Mg] Annealing
symbol loation (bp) (mmol) temperature
D16S519 16p12 0.81 AGCTTACCAGTCTCACAGGG AAACCATGCTTGTCTAGCC 135-157 2.0 58-C
D16S419 16q12-13 0.76 ATTTTAAAGGAATGTAAAGNACACA GACGTTAGACCAGGAGTCAG 146-164 1.5 56^C
D16S514 16q21 0.82 CTATCCACTCACTTTCCAGG TCCCACTGATCATCTTCTC 117-129 1.5 56^C
D16S512 16q22.1 0.82 TGAGAGCCAAATAAATAAATGG ATAAGCCACTGCGCCCAT 201-211 2.0 58^C
D16S518 16q23.1-24.2 0.83 GGCCTTTTGGCAGTCA ACCTTGGCCTCCACAC 272-290 2.0 57-C
D16S520 16q24 0.84 GCTTAGTCATACGAGCGG TCCACAGCCATGTAAACC 181-197 2.0 58-C
D16S413 16q24.3 0.84 ACTCCAGCCCGAGTAA GGTCACAGGTGGGTTC 131-149 1.5 56:Ca
a1O% DMSO.
Table 2 Wilms' tumour samples used in WT1 mutation analysis
No. Tumour sample Disease stage Histopatdxogy Status (LOH)
(GOS no.)
1 249 1 Mononorphous epithelial Alive (No)
2 145 3 FFa Alive (No)
3 16 3 FH Alive (No)
4 54 3 FH Alive (No)
5 55 2 FH Alive (No)
6 101 1 UH Relapsed/alive (Yes)
7 185 1 FH Alive (No)
8 120 4 FH Alive (No)
9 132 1 FH Alive (No)
10 90 1 FH Alive (No)
11 244 3 FH Alive (No)
12 219 1 FH Alive (No)
13 129 3 FH Alive (No)
14 231 Bilateral FH Alive (No)
15 100 2 FH Alive (No)
16 207 1 FH Alive (No)
17 44 4 FH Alive (No)
18 89 3 FH Alive (No)
19 135 3 FH Alive (No)
20 146 1 FH Alive (No)
21 218 Bilateral FH Alive (No)
22 126 3 FH Alive (No)
23 51 3 FH Alive (No)
24 360 1 FH Alive (No)
25 270 4 FH Alive (No)
26 399 1 Mononorphous epithelial Alive (No)
27 407 3 UH Relapsedied (No)
28 446 1 FH Alive (No)
29 206 4 FH Alive (Yes)
30 234 3 FH Alive (No)
31 169 4 FH Alive (Yes)
32 439 3 FH Alive (No)
33 178 1 FH Alive (No)
34 66 Bilateral FH Alive (Yes)
35 542 3 FH Relapsed/died (Yes)
36 505 Bilateral FH Alive (No)
37 119 1 FH Alive (No)
38 96 4 FH Alive (No)
39 198 Bilateral FH Relapsed/died (Yes)
40 358 4 FH Relapsed/alive (No)
amn the absence of anaplastic nuclear changes the term favourable histology (FH) is used because ofthe generally good outcome forthese patients.
for each ofthe microsatellite primer pairs are detailed in Table 1. The
CA stund primer was radiolabelled with gamma -'P (0.4ACi) using
polynucleotide kinase (NBL). The PCR was performed using a
Biometra thermal cycler in a reaction volume of 10 R1 containing
50-100ng oftumourorconstitutionalDNA. dNTPs at afinal concen-
tration of 0.2 mm. 1.5-2 mmol of magnesium chloride. 1-2 pmiol of
labelled and unlabelled primer. Taq DNA polymerse 0.5 U and lX
Buffer (Bioline). The step cycle file comprised 3 miM ofdenaturation
at 94°C. 30 cycles of 94°C for 30s. annealing at the appropriate
temperature for 30s and extension at 720C for 30 s. The annealing
temperature varied with eachprimersystem (Table 1). Oncompletion.
6 1 of stop solution (Gibco BRL) was added to each sample and
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denatured at 950C for 3 min. An aliquot of3j1 ofthe resultant solu-
tion was loaded onto a 6% denaturing polyacylamide gel. The gel
was run at 60W constant power in 1 x Tns actate EDTAbuffer, the
lengtioftime depended on thefiagnt size. Gels werethenfixed in
10% methaVo10% acetic addbefore dryingandexposure toXAR-5
film (Kodak) for 12-72 h without an intensifying screen.
Tumour samples were collected between May 1983 and May
1990. All patients referred to the Hospital for Sick Children, Great
Ormond Street. with a histopathological diagnosis of Wilms'
tumour were treated on sequential United Kingdom Children's
Cancer Study Group protocols UKWI and UKW2 (Pritchard et al,
1995; CD Mitchell, personnal communication). All children
received uniform treatment as per the protocol and have been
followed up for at least 7 years.
RESULTS
In all, 40 Wilms' tumours from patients who presented to the
Hospitals for Sick Children, London, were available for LOH
analysis. Following the clinical diagnosis of a 'Wilms' tumour', the
patients underwent nephrectomy and DNA was prepared from the
tumours. The clinicopathological details of these 40 Wilms'
tumours are summarized in Table 2. Two of the tumours analysed
in this study were also of a very unusual histological subtype,
showing monomorphous epithelial changes. These tumours arose
in a brother and sister, their mother had been cured of a Wilms'
tumourby nephrectomy 20 years previously. In view ofthis history
offamilial Wilms' tumour, GOS 149 and 399 alone cannot be clas-
sified as sporadic Wilms' tumours, but were still analysed for LOH
on 16q. All of the microsatellite polymorphic markers tested had a
frequency of heterozygosity above 0.73 and all 40 patients were
CIrbmr
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101
heterozygous at three or more of the ten polymorphic loci tested.
The physical location of the polymorphic microsatellite markers
was obtained from Kozman et al (1995) and Doggett et al (1995)
and from the Genome database (Gyapay et aL 1994).
Clinikoathological details of the tumours
Of the 40 patients analysed in this study. 13 had stage 1 disease.
two stage 2, 13 stage 3. seven stage 4 and five had bilateral
disease. Thirty-eight patients had 'favourable' histology (FH)
tumours and two had 'unfavourable' histological features (UH).
Five children relapsed and three ofthese patients died of disease.
with two being cured by second-line therapy.
Loss of heerozygosity on chromosome 16
Constitutional and tumour DNA from 40 patients were used to
investigate the frequency of LOH along the long arm of chromo-
some 16. using seven polymorphic microsatellite markers
(D16S413, D16S 520, D16S 518, D16S 512, D16S 514. D16S 419
and D16S519). The physical location of the polymorphic
microsatellite markers is shown in Table 1 and was determined
from the genome database and current literature (Gyapay et al
1994; Doggett et al 1996). All polymorphic microsatellite markers
had a heterozygosity frequency above 0.75 (see Table 1).
Six (15%) of 40 informative Wilms' tumours - GOS 66, GOS
101, GOS 169, GOS 198, GOS 206, GOS 542 - showed LOH for
markers on 16q. In these six cases there was loss of one allele in
the tumour compared with constitutional DNA. No homozygous
deletions were detected. The results of the LOH analysis are
shown in Figure 1 and diagrammatically in Figure 2. In two ofthe
GOS
169
GOS
19B
J LOH-2
JLOH-1
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Fig 2 ?m
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six tumours showing LOH - GOS 101 and 169 - demonstrable
allelic loss was restricted to the 16q23-qter region. The other four
tumours. GOS 66. GOS 198, GOS 206 and GOS 542, also showed
LOH for the D16S520 locus, making this the single. consistent
region lost in all tumours. The more distal D16S413 locus shows
LOH in three tumours, but whether this region is also involved in
tumours GOS 66, GOS 198 and GOS 542 cannot be determined
because these tumours were not informative at this locus. None of
the tumours experienced LOH distal to the D16S514 locus, which
showed LOH in three tumours and possibly in GOS 206, which
was uninformative at this locus. Tumours GOS 66. GOS 198 and
also GOS 206 all show LOH for at least one locus proximal to
D16S518 but, because some ofthe interstitial markers were consti-
tutionally homozygous in these tumours, it could not be demon-
strated whether any loci within the D16S514-D16S520 interval
had retained heterozygosity. From the analysis of these five
tumours. therefore, the results are consistent with LOH being initi-
ated at a defined point along 16q. which is different in different
tumours. and extending distally to 16qter. Tumour GOS 542.
however, shows LOH or constitutional homozygosity for the
16q23.2-qter region, as well as LOH for D16S514 in 16q21.
Heterozygosity is retained at the intervening D16S512 locus. In
this tumour. therefore, there is demonstrable discontinuity in LOH.
thereby defining a second distinct region that potentially contains a
tumour-supressor gene(s) (Figure 2). The most proximal marker
tested was D16S519. which mapped to 16pl2. This marker was
informative in all tumours except GOS198 and. in all of the
tumours. both alleles were retained (Figure 1). Thus. from the
summary shown in Figure 2. two regions of distinct LOH can
clearly be identified.
Clinical outcome and LOH for 16q
Three of the 40 patients with Wilms' tumour in this series. GOS
198. 407 and 542. died of disease and the tumours from two of
these. GOS 198 and 542. showed LOH for markers on 16q. Two
other patients. GOS 101 and 358. relapsed but were cured by
second-line therapy (see Table 2). One ofthese recurrent tumours.
GOS101. also showed LOH for 16q. Although this tumour was
stage 1 by clinicopathological staging. it had unfavourable histo-
logical features. GOS 407 was a stage 3 tumour with unfavourable
histological features and this patient died I month after relapse.
There was no evidence for LOH for 16q markers in this tumour.
Overall, therefore, two ofthe three patients who died ofthe disease
had LOH for 16q. The only patient with stage 1 disease, who
relapsed. also showed LOH for this region (Table 2). These obser-
vations demonstrate the tendency for LOH to occur in higher stage
disease or with unfavourable histological features. Furthernore,
three out offive patients thatrelapsed, also had LOH for 16q. Even
though the patient numbers are small, and because this was aretro-
spective study using a selected series oftumours, these results still
provide strong evidence for a trend towards worse outcome in
patients with LOH for 16q.
DISCUSSION
We have performed LOH analysis in a series of 40 patients with
sporadic Wilms' tumour to investigate whether allelic loss on the
long arm of chromosome 16 is associated with poor prognosis.
Our study found tumour-specific LOH for markers on 16q in 6
(15%) of 40 tumours. Although the frequency of LOH is slightly
lower than in other studies (Coppes et al. 1992: Maw et al. 1992:
Grundy et al 1994; Austruy et al. 1995). this probably simply
reflects minor statistical variation as a result of (1) the relative
numbers of tumours used in different studies. (2) the number of
specific markers used and (3) the means ofdetecting the polymor-
phisms. The overall mean frequency of LOH is approximately
20%. It is also possible. however, that minor differences in the
frequency ofLOH between studies may reflect genetic differences
between different racial groups.
The study by Maw et al (1992) provided molecular evidence for
the existence of two discrete regions of LOH on 16q. Region
16ql3 was implicated by the discovery of an interstitial deletion
between 16q13 and 16q21 in a single tumour. A second tumour
had an interstitial deletion. but the extent of the deletion could not
be defined because not all of the probes that were used between
16q11.2 and q21 were informative. In five other tumours in this
study, LOH was restricted to the 16q22-qter region (Maw et al.
1992). From ouranalysis it was also possible toestablish, unequiv-
ocally. that two distinct regions of 16q show LOH in Wilms'
tumorigenesis. Clearly LOH for the 16q24-qter region was the
most consistent finding but one of the six tumours showed LOH
that was restricted to the 16q21 region. Tumours from several
patients showing larger regions of LOH were. unfortunately.
constitutionally homozygous at critical loci. and so whether any of
the othertumours in fact showed 16q21-specific LOH could not be
determined (Maw et al, 1992). Importantly. none of these six
tumours showed LOH extending to 16q13. which means that, in
combination with previous studies, the proximal site ofany poten-
tial tumour-suppressor gene is restricted to 16q21. In two other
studies (Grundy etal, 1994: Coppes et al. 1992). only polymorphic
markers that mapped to the telomeric region of 16q were used and
so cannot confirm the location of a putative Wi1ms' tumour (WT)
gene in 16q21. Newsham et al (1995), on the other hand. concen-
trated on the 16q13 region and found that 20% oftheir panel of26
tumours showed LOH for the 16q13-21 region. No markers
mapping distal to 16q22.1 were used in this study, however. and so
it was notdetermined whether LOH extended all the way to 16qter.
Recently, Austruy et al (1995) used a number of markers distrib-
uted along the length of 16q and identified LOH in 7/25 tumours.
The region of allelic loss extended from 16qter to D16S419 in
16ql2-13. which is consistent with our study. Taken together.
therefore, LOH studies for chromosome 16 in Wilms' tumour
clearly define the 16q24-qter region as the most common site of
allelic loss. The evidence for a tumour-supressor gene in 16q21 is
still based on only a limited number of observations, which may
indicate that genes in these regions are less critical in establishing
the tumour phenotype. Interestingly. the der (16) t(1:16) (q21;q13)
cytogenetic abnormality was noted in 10% of those tumours that
could be karyotyped successfully (Matthew et al. 1996). All of
these tumours were of favourable histology and the cytogenetic
abnormality did not confer an adverse prognosis (Matthew et al.
1996). Whether the breakpoint in this tumour inactivates a critical
tumour-supressor gene has not been determined, but if this is the
case then loss of function of this particular gene does not lead to
adverse outcome.
From our studies, a clear association between LOH on 16q and
higher stage/worse outcome tumours was apparent. Overall, there-
fore. two ofthe three patients who died ofthe disease in this series
had LOH for 16q. The only patient with stage 1 disease who
relapsed also showed LOH for this region. demonstrating a
tendency for LOH to occur in higher stage disease or predict poor
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prognosis in patients with stage 1 disease. Furthermore, all but one
of the tumours with LOH for 16q markers were stage 3/4 or had
bilateral disease at diagnosis. The remaining (sixth) tumour with
LOH for 16q markers (GOS101) was stage 1 at diagnosis but had
unfavourable histological features (anaplasia). This tumour
recurred, but, following second-line treatments the child is alive
with no detectable disease. Although the presence of anaplasia
confers an adverse prognostic sign, it is stage related, and does not
significantly alter the outcome of patients with stage 1 disease
(D'Angio, 1989). Given the observation of Grundy et al (1994),
who noted that LOH on 16q was associated with adverse outcome,
irrespective ofthe stage orhistological features ofthe tumour, it is
likely that the molecular alteration in GOS 101 is more significant
than the presence ofanaplasia Austruy et al (1995) detected LOH
for 16q markers in 7 of 25 Wilms' tumours. Two of these were
considered to be stage 1 at diagnosis and in both cases the tumour
recurred; one patient was subsequently cured, but the other died of
disease, again supporting the hypothesis that allelic loss on 16q
represents an adverse prognostic marker, irrespective of the
disease stage.
Wbether the 16q locus will prove to be Wilms' tumour specific is
still not clear at this time. A numberofothertmo types have been
found to exhibit LOH from 16q, usually in addition to a number of
other chromosomal abnoralities. The region of allelic loss in a
numberofdifferenttumour types also appears to involve 16q22-qter
(Mugneret et al, 1988; Sato et aL 1990; Tsuda et al, 1990;
Bergerheim et al, 1991; Fujimori et al, 1991; Thomas et al, 1991;
Douglass et al, 1990; Dorion-Bonnet, et al 1995), the same as that
involved in Wdlms' tumour, although still arelatively largeregion.
Nephroblastomatosis is considered by some to be a precursor
lesion for Wllms' tumour based on (a) histopathological analysis
(Beckwith et al, 1990) and (b) the discovery ofWTI mutations in
two patients with so-called nephrogenic rests (Park et al, 1993).
LOH for markers in 16q13-qter has also been reported in one case
ofnephroblastomatosis (Austruy et al, 1995). Although interesting,
this observation conflicts with the hypothsis that genes on chro-
mosome 16q are implicated in tumour progression rather than
tumour initianon and, further, that the presence ofLOH on 16q is
associated with a poor prognosis (Grundy et al, 1994). It should be
noted that, in the kidney showing nephroblastomatosis, the tissue
sampled was from the immediate vicinity of the tumour, which
raises the possibilityofsamplecontamination (Austruy etal, 1995).
Wiedemann-Beckwith syndrome (WBS) is considered to be a
Wilms' tumour predisposition syndrome (Wiedemann 1983), and
has been associated with chromosome region llpl5 by linkage
studies in familial cases and the presence ofcytogenetic abnormal-
ities involving this region (Koufos et al, 1989; Ping et al, 1989;
Weksberg et al, 1993) in patients with WBS. Recently, chromo-
some 16 has been implicated in this syndrome in two patients
(Weksberg et al, 1993; Newsham et al, 1995) and in the Wllms'
tumour ofa patient with WBS (Austruy et al, 1995). Both ofthese
WBS patients had constitutional translocations derived from
phenotypically normal mothers. The first (Weksberg et al, 1993)
carried a t(l1;16) (pl5.5;ql2) and the second (Newsham et al,
1995) a t(11;16) (pl5.5;ql3). One of the tumours studied by
Austray et al (1995) was obtained from a patient with WBS. LOH
was apparently restricted to 16ql3 in the tumour DNA from this
patient and exctends over an estimated 8-cM region. This tumour-
specific deletion of 16q13 markcers provides further evidence for
the independent involvement ofa gene at 16ql3 in Wilms' tumori-
genesis. A number of patients with WBS and maternally derived
translocations have now been reported (Weksberg et al 1993;
Mannens et al 1994) and, although lpl15.5 was always involved.
chromosome 16 was not a consistent partner chromosome.
Furthermore, ofthe two WBS patients with an 11;16 translocation.
one is alive with no evidence ofaWilms' tumour. the otherdied in
the neonatal period (Weksberg et al, 1993; Newsham et al, 1995).
There is some evidence for an association between cytoge-
neticdmolecular abnormalities on chromosomes 11 and 16 in
Wllms' tumours. Two studies have analysed LOH in Wilms'
tumours on both llp and 16q. The initial study found LOH for
both chromosomes in only three of nine tumours (Maw et al,
1992). Similar findings were reported by Coppes et al (1992). who
observed loss of chromosomal material on chromosomes 11 and
16 in three of six tumours. In our study, four of the six Wilms'
tumours showing LOH on 16q had previously been analysed for
LOH on chromosome 11 (Wadey et al, 1990). Two of these four
tumours showed LOH for markers on both 11 and 16. The other
two tumours were not included in the LOH analysis of lIp. The
fact that LOH on 16q can occur independently of LOH on lIp
possibly suggest that the sequential occurrence ofthese two events
is not required fortumorigenesis. However, LOH does not identify
mutations in specific genes and so the relative contribution of
genes on lIp and 16q will only be resolved when these genes have
been characterized.
The association between LOH on 16q and an adverse outcome is
clearly potentially very important for future clinical studies, partic-
ularly as patients entering clinical trials in the United Kingdom are
randomized between immediate nephrectomy vs percutaneous
biopsies before preoperative chemotherapy (C Mitchell, personal
communication). In order to evaluate LOH on 16q as a prognostic
indicator, larger prospective studies involving all of the patients
enrolled into the specific trials would be required. Furthermore, if
the same polymorphic markers used in the current NWTS-5 trial
are used to determine LOH for 16q in future studies, then the
frequency of LOH for 16q will be directly comparable. Although
there is increasing evidence that LOH for 16q may help stratify
patients into those with biologically favourable or unfavourable
disease, this possibility needs to be confirmed by analysis oflarger
numbers of patients. Confirmation of this relationship would
possibly enable 'fine tuning' of available therapies for Wilms'
tumour with the possibility of reserving the use of doxorubicin,
which is cardiotoxic, for use in those patients with adverse biolog-
ical and clinicopathological features. These extended studies may
also serve to further narrow down the critical region of 16q.
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